Lenacapavir

CAS Number: 2189684-44-2

Molecular Formula: C39H32ClF10N7O5S2

Therapeutic: Antiretroviral medication HIV/AIDSPharmacological Class: Direct-Acting Antiviral (DAA)Specific Drug Class: Capsid InhibitorFluorinated indazoles drug designGMP grade Lenacapavir precursorWholesale HIV drug precursorIodo/Fluoro-Functional IntermediateNitrogenous Heterocycle

About Lenacapavir

Lenacapavir Intermediate (CAS 2189684-44-2), chemically known as 6-(3-amino-2,6-difluorophenyl)-5-fluoro-1-(2,2,2-trifluoroethyl)-1H-indazole-3-carboxylic acid, is a sophisticated trifluorinated indazole scaffold. In Elemental Derivatives hierarchy (Halogen/Nitrogen Heterocycles), it represents the pinnacle of multi-st...

Lenacapavir Specifications

CAS Number

2189684-44-2

Molecular Formula

C39H32ClF10N7O5S2

Molecular Weight

968.29

IUPAC Name

N-[(1S)-1-[3-[4-chloro-3-(methanesulfonamido)-1-(2,2,2-trifluoroethyl)indazol-7-yl]-6-(3-methyl-3-methylsulfonylbut-1-ynyl)-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-5,5-difluoro-9-(trifluoromethyl)-7,8-diazatricyclo[4.3.0.02,4]nona-1(6),8-dien-7-yl]acetamide

Canonical SMILES

CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)[C@H](CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C([C@H]7C[C@H]7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C

InChI Key

BRYXUCLEHAUSDY-WEWMWRJBSA-N

InChI

1S/C39H32ClF10N7O5S2/c1-36(2,63(3,59)60)10-9-21-5-6-22(23-7-8-26(40)30-32(23)57(17-37(43,44)45)54-35(30)55-64(4,61)62)31(51-21)27(13-18-11-19(41)14-20(42)12-18)52-28(58)16-56-34-29(33(53-56)39(48,49)50)24-15-25(24)38(34,46)47/h5-8,11-12,14,24-25,27H,13,15-17H2,1-4H3,(H,52,58)(H,54,55)/t24-,25+,27-/m0/s1

UNSPSC Code

EU custom code: CN 29359090

HSN No

293590

CAS Number

2189684-44-2

Molecular Formula

C39H32ClF10N7O5S2

Molecular Weight

968.29

IUPAC Name

Canonical SMILES

CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)[C@H](CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C([C@H]7C[C@H]7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C

InChI Key

BRYXUCLEHAUSDY-WEWMWRJBSA-N

InChI

UNSPSC Code

EU custom code: CN 29359090

HSN No

293590

Molecular Weight

968.29

Density (Predicted)

1.621+0.14 g/cm3 Temp: 25°C; Press: 760 Torr 4.723+0.30

pKa (Predicted)

Most Acidic Temp: 25 °C

Regulatory Synonyms

GS 6207, GS 714207, GS-CA-2, GS-HIV

Critical Features

Contains the 2,2,2-trifluoroethyl group and Indazole-3-carboxylic acid moiety

Clinical Indication

Multidrug-Resistant (MDR) HIV-1 Treatment & HIV Pre-Exposure Prophylaxis (PrEP)

Capsid Inhibition

Disruption of HIV-1 capsid assembly and disassembly studies, Indazole core mimics natural protein-protein interface binders

Multistage Mechanism

Inhibits HIV-1 replication at multiple stages—including capsid-mediated nuclear uptake of proviral DNA and assembly/maturation of new progeny

Salvage Therapy

Primary therapeutic use is for "Heavily Treatment-Experienced" (HTE) adults. New class-no cross-resistance with older drug classes (like INSTIs or NNRTIs)

Pharmacokinetic Advantage

Poly-fluorinated nature allows final drug to remain therapeutic in the body for up to 6 months after a single subcutaneous injection

Route 1 (Discovery/Standard)

Suzuki-Miyaura coupling of the indazole core with a boronic acid derivative. Favoured route for its high regioselectivity but often requires expensive palladium catalysts

Route 2 (Process Optimization)

Utilizes a "One-Pot" or convergent synthesis focusing on early-stage fluorination and cyclisation to reduce metal waste. Preferred route for B2B-Procurement Managers looking for cost-efficiency and "Green Chemistry" metrics

Secondary Therapeutic Potential

(Oncology) Potential as a GCN2 kinase inhibitor or in targeting specific growth factor pathways (Anti-Inflammatory) Some derivatives of this scaffold show activity in inhibiting S1P receptors